PMID- 28969086
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220410
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 38
DP  - 2017 Sep 8
TI  - Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major 
      sarcoma center in China.
PG  - 64471-64480
LID - 10.18632/oncotarget.16293 [doi]
AB  - PURPOSE: This study was conducted to review the efficacy and safety of Apatinib 
      in stage IV sarcoma patients who failed previous chemotherapy. MATERIALS AND 
      METHODS: The clinical information on 16 patients with stage IV sarcomas who 
      failed in prior chemotherapy and subsequently received Apatinib treatment was 
      collected. Apatinib was given 500mg/daily and 4 weeks as a cycle. All patients 
      had at least one measurable extracranial tumor according to Response Evaluation 
      Criteria In Solid Tumors 1.0 criteria. Progression free survival (PFS), overall 
      survival (OS), objective response rate (ORR), disease control rate (DCR) and 
      treatment-related adverse effects (AEs) were reviewed and evaluated. RESULTS: 
      Patients was administered Apatinib for 0 to 9 cycles with the median of 3.2 
      cycles. Median follow-up time was 8.4 months (1 to 12 months). Ten of 16 patients 
      received at least 1 complete cycle of Apatinib treatment were eligible for the 
      efficacy analysis. The median PFS was 8.84 months. Two patients achieved partial 
      response (PR) and 6 patients achieved stable disease (SD). Two patients were 
      evaluated as progression disease (PD) and one patient died of disease 
      progression. The ORR was 20.0% (2/10) and the DCR was 80.0% (8/10). The most 
      common grade 3/4 treatment-related AEs were hypertension (18.7%), hand-foot 
      syndrome (12.5%) and proteinuria (6.3%). No drug-related severe AEs occurred. 
      CONCLUSION: CApatinib treatment in this exploratory study exhibited objective 
      efficacy and manageable toxicity in stage IV sarcoma patients who failed in 
      chemotherapy. This result supports future random controlled trial to further 
      define Apatinib activity in stage IV sarcomas.
FAU - Li, Feng
AU  - Li F
AD  - Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
AD  - National Clinical Research Center of Cancer, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
FAU - Liao, Zhichao
AU  - Liao Z
AD  - Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
AD  - National Clinical Research Center of Cancer, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
FAU - Zhao, Jun
AU  - Zhao J
AD  - Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
AD  - National Clinical Research Center of Cancer, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
FAU - Zhao, Gang
AU  - Zhao G
AD  - National Clinical Research Center of Cancer, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
AD  - Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, 
      Tianjin, People's Republic of China.
FAU - Li, Xubin
AU  - Li X
AD  - National Clinical Research Center of Cancer, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
AD  - Department of Radiology, Tianjin Medical University Cancer Institute & Hospital, 
      Tianjin, People's Republic of China.
FAU - Du, Xiaoling
AU  - Du X
AD  - Department of Diagnostics, Tianjin Medical University, Tianjin, People's Republic 
      of China.
FAU - Yang, Yun
AU  - Yang Y
AD  - Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
AD  - National Clinical Research Center of Cancer, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
FAU - Yang, Jilong
AU  - Yang J
AD  - Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
AD  - National Clinical Research Center of Cancer, Tianjin Medical University Cancer 
      Institute & Hospital, Tianjin, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20170316
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5610018
OTO - NOTNLM
OT  - Apatinib
OT  - clinical benefit response
OT  - efficacy
OT  - progression free survival
OT  - sarcoma
COIS- CONFLICTS OF INTEREST The authors declare that they have no conflict of interest.
EDAT- 2017/10/04 06:00
MHDA- 2017/10/04 06:01
PMCR- 2017/09/08
CRDT- 2017/10/04 06:00
PHST- 2016/10/06 00:00 [received]
PHST- 2017/03/01 00:00 [accepted]
PHST- 2017/10/04 06:00 [entrez]
PHST- 2017/10/04 06:00 [pubmed]
PHST- 2017/10/04 06:01 [medline]
PHST- 2017/09/08 00:00 [pmc-release]
AID - 16293 [pii]
AID - 10.18632/oncotarget.16293 [doi]
PST - epublish
SO  - Oncotarget. 2017 Mar 16;8(38):64471-64480. doi: 10.18632/oncotarget.16293. 
      eCollection 2017 Sep 8.